In 2017, Forbes listed 30 potential Chinese medical and health enterprises

Forbes China recently released the "2017 China potential enterprise list", presenting three lists for the first time, including the list of potential enterprises of listed companies, the list of potential enterprises of non listed companies and the new third board enterprises that deserve attention Among them, there are 100 potential listed enterprises, 100 potential new third board enterprises and 20 potential non listed enterprises, totaling 220 enterprises The industries involved are concentrated in electronics, chemical industry, medicine, etc The author "digs out" 30 enterprises in the field of medical and health, accounting for more than 13% of the total, for the readers Among these 30 enterprises in the field of medical and health care, there are 29 listed enterprises, including 4 new third board enterprises worthy of attention, 17 Shenzhen Stock Exchange listed enterprises, 7 Hong Kong Stock Exchange listed enterprises and 1 Shanghai Stock Exchange listed enterprise From the perspective of subdivision, most of them are pharmaceutical enterprises, and the results of the author's statistics are 22, including pharmaceutical, API production, preparations and blood products, etc Other enterprises are diagnostic reagents, diagnostic treatment equipment, medical auxiliary equipment, etc In terms of geographical distribution, half of the enterprises are located in Guangdong, Shanghai and Zhejiang, followed by Beijing and Shandong Enterprises in Guangdong Province are mainly located in Guangzhou, Shenzhen and Zhuhai, while Shaoxing is the majority in Zhejiang Province, followed by Hangzhou and Ningbo The selected enterprises in this list of potential enterprises in China are required to have an operating revenue of between 10 million and 1 billion yuan in 2015 and achieve profitability The author will introduce the non listed enterprises and the new third board enterprises which are worthy of attention In 2017, the potential enterprises of China's unlisted companies were listed in Jiangxi Tonghe Pharmaceutical Co., Ltd in 2015, Tonghe pharmaceutical was also a potential unlisted enterprise, so it was included in the potential unlisted enterprises by Forbes China Shortly after the list was released, on March 31 of this year, Tonghe Pharmaceutical Co., Ltd completed an IPO of 289 million yuan and officially listed on the growth enterprise market of Shenzhen stock exchange with the stock code of 300636 and the latest valuation of 2684 million yuan This enterprise is mainly engaged in the production of APIs and intermediates Its production capacity and product quality of main varieties are at the leading level in China It is exported to more than 40 countries and regions around the world with an export rate of more than 95% The operating revenue in 2015 and 2016 was about RMB 275 million and RMB 250 million respectively In 2016, the return on net assets reached 21.04% In 2017, Shanghai New Vision Medical Equipment Co., Ltd., a new third board enterprise worthy of attention, is a high-tech enterprise specialized in medical digitization, medical informatization, intelligent medical product research and development, production and sales, in addition to designing the business of medical investment and management Founded in Shanghai Tongji University National Science and Technology Park in 2005, obtained the national innovation fund in 008, with 13 patents and copyrights In November 2011, it was invested by Shanghai municipal government venture capital foundation In December of the same year, it successfully acquired a professional medical software development company, developing from a single department product to dozens of comprehensive products In September 2012, new vision became the first listed company on the third board of Ophthalmology Through the integration of clinical needs and cutting-edge technology, an integrated medical digital product and medical information solution has been formed The current market value has reached 1.483 billion New vision products and solutions: Shanghai Baiao Technology Co., Ltd Baiao technology focuses on the development, production and sales of clinical individualized drug gene diagnosis products and supporting equipment hybridizer and reader, and owns the "color gene chip core technology system" with independent intellectual property rights In November 2013, Baiao technology was listed on the new third board, with a current market value of 742 million yuan Since 2005, the FDA of the United States has approved the listing of personalized drug genetic diagnosis products In September 2009, Bai Ao technology obtained the registration approval of CFDA, the first individual drug gene testing product in China After more than ten years of efforts, the products of Bayao technology have successively obtained the production license of class I, class II and class III medical devices, and have been sold in more than 300 top three hospitals Wuhan Mingde Biotechnology Co., Ltd In the field of in vitro diagnosis, there is such a new three board company, specializing in the R & D, production and sales of in vitro diagnostic reagents and supporting instruments (POCT \ molecular diagnosis \ chemiluminescence, etc.), with more than 30 POCT rapid diagnostic reagent products registered by CFDA, covering many fields such as cardiovascular and cerebrovascular diseases, infectious diseases, kidney disease, diabetes, health examination and obstetrics and Gynecology, which has become a domestic company POCT product line is one of the most comprehensive enterprises This enterprise is called "Mingde biology", founded in 2008, located in Wuhan Optical Valley biology city In 2012, CE certificate and ISO13485 certificate were successively obtained The clinical application of diagnostic reagents of Mingde biology is convenient, and most of them can obtain the test results within 15 minutes, which can not only meet the needs of large-scale general hospitals for rapid detection of critical cases, but also make up for the lack of testing resources in grass-roots hospitals and community hospitals Since its debut on the new third board in 2014, Mingde biology has made outstanding performance and won the first place in the value ranking of the new third board in 2016, with a market value of more than 2 billion yuan On March 23 last year, Mingde biology changed from market making transfer to agreement transfer and planned to list a shares Mingde biological immune quantitative analyzer Shenzhen new industry Biomedical Engineering Co., Ltd Since its establishment in 1995, new industrial biology has been focusing on the research and development, production and sales of chemiluminescent immunoassay instruments and in vitro diagnostic reagents It is the first company in China to use "nano immunomagnetic beads" as the key separation materials of the system, and the first company to use "synthetic small molecular organic compounds" instead Traditional enzymes are used as luminescent markers In 2008, new industrial biology successfully developed the first fully automatic chemiluminescent immunoanalyzer and supporting reagents in China, which was officially launched in 2010 In 2016, we launched a new product, the automatic chemiluminescent instrument maglumi 4000 plus At present, the company has obtained 23 invention patents, 17 software copyrights, 102 chemiluminescent reagent registration certificates, 5 joint registration certificates, etc Immune products of new industrial biology on July 25, 2014, new industrial biology was listed on the new third board, with a market value of more than 18 billion yuan In February 2016, the transfer of new industries was suspended on the new third board and IPO planning began.